Document text
Principal Investigator: Jiaxin Liang
Organization: DANA-FARBER CANCER INST
Fiscal Year: 2024
Award: $128,798
Funding agency: National Cancer Institute
Project Summary: Immunotherapies have revolutionized the clinical treatment of melanoma; however, these
treatment strategies have been ineffective in treating late stage and metastatic melanoma lesions with overall
patient response rates below 50% illustrating an unmet medical need in melanoma therapy.
We have previously demonstrated that mitochondrial metabolism played an important role in melanoma
metastasis and hence, I sought to investigate the role of mitochondria in facilitating this aggressive form of the
disease. Interestingly, our preliminary results indicate that specific deletion of mitochondrial complex I subunit
Ndufs4 in tumor cells led to a dramatic anti-tumor immune response. Proteomic and metabolomic analyses of
the tumor samples reveal that mitochondrial complex I inhibition induces an upregulation of proteins involved in
antigen presentation, and a shift of choline metabolism from choline-sarcosine pathway to choline-
phosphatidylcholine pathway. Tumor-Infiltrating Lymphocytes (TIL) analyses reveal a significant increase of NKT
cells. However, the mechanisms by which mitochondrial complex I inhibition induces antigen presentation,
metabolic flux shift and NKT cell activation are still waiting to be explored.
Based on our encouraging preliminary results, I seek to further explore the mechanisms whereby mitochondrial
complex I activity in tumor cells modulates immune response in tumor microenvironment by focusing on three
Aims. In Aim-1, I will determine the mechanisms of how mitochondrial complex I inhibition enhances MHC-I
dependent antigen presentation. In Aim-2, I plan to determine the mechanisms whereby mitochondrial complex
I inhibition causes the metabolic shift, choline-betaine to choline-phosphatidylcholine, and its potential roles in
NKT cell recruitment and activation. Finally, in Aim-3 I will evaluate the efficacy of combination treatment of
immune checkpoint inhibitors with mitochondrial complex I inhibition in preclinical mouse melanoma models.
While Aims 1 and part of 2 will be completed during the training stage, part of Aim 2 and the entire Aim 3 will be
conducted during the independent phase of the award.
The extensive training in different fields proposed in this application including proteomics, metabolomics and
immunology will provide the tools to for me to become an independent researcher and study the mechanisms of
which mitochondrial complex I regulates immune response in the tumor microenvironment. This training will be
received in the vibrant scientific communities of Dana-Farber Cancer Institute and Harvard Medical School. This
environment will expose me to the collaborations and discussions necessary for career development and future
opportunities. Dr. Puigserver mentorship will be supportive to establish those connections and actively guide me
in talk and manuscript preparation, student mentorship, experimental design, and career development. Together,
the research and career development plans proposed in this application will strengthen my skills and
competitiveness to become an independent researcher at a major institution.
Terms: <Antigen Presentation><Award><BS-seq><Betaine><Bisulfite-based sequencing><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cell Body><Cells><Checkpoint inhibitor><Choline><Choline Glycerophospholipids><Choline Phosphoglycerides><Clinical><Clinical Treatment><Clinical Treatment Moab><Collaborations><Combined Modality Therapy><Communities><Complex><DF/HCC><Dana-Farber Cancer Institute><Data><Development Plans><Development and Research><Disease><Disorder><Down-Regulation><Ectopic Expression><Environment><Enzyme Gene><Enzymes><Evaluation><Experimental Designs><Future><Goals><Immune><Immune Surveillance><Immune checkpoint inhibitor><Immune mediated therapy><Immune response><Immunes><Immunocompetent><Immunologic Surveillance><Immunologic Surveillances><Immunological Surveillance><Immunological Surveillances><Immunological response><Immunologically Directed Therapy><Immunology><Immunomodulation><Immunosurveillance><Immunotherapeutic agent><Immunotherapy><Impairment><In Vitro><Institution><Intermediary Metabolism><Intrinsic drive><Investigators><Knock-out><Knockout><LYT3><Lecithin><Lesion><Lipids><Lycine><Malignant Melanoma><Manuscripts><Maps><Medical><Melanoma><Melanoma Cell><Melanoma Metastasis><Melanoma patient><Mentorship><Metabolic><Metabolic Processes><Metabolism><Metastatic Melanoma><Methylation><Methylglycine><Mice><Mice Mammals><Mitochondria><Modeling><Monoclonal Antibodies><Multimodal Therapy><Multimodal Treatment><Murine><Mus><N-Methylglycine><N-methyl-glycine><NADH><Nivolumab><Opdivo><Outcome><Oxyneurine><Pathway interactions><Peptides><Phase><Phosphatidylcholine Biosynthesis><Phosphatidylcholines><Play><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Preparation><Production><Protein Modification><Proteins><Proteomics><R & D><R&D><Regimen><Research Personnel><Researchers><Resistance><Role><Sampling><Sarcosine><Site><Students><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Teff cell><Testing><Therapeutic><Training><Transplantation><Tumor Cell><Tumor Immunity><Tumor-Infiltrating Lymphocytes><Up-Regulation><Upregulation><Yervoy><anti-tumor immune response><anti-tumor immunity><antitumor immunity><bisulfite sequencing><bisulfite-seq><cancer immunity><cancer microenvironment><career development><combination therapy><combined modality treatment><combined treatment><determine efficacy><effector T cell><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><exhaust><formyl peptide><glycine dehydrogenase><host response><immune check point inhibitor><immune competent><immune drugs><immune modulation><immune regulation><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogenic><immunogenicity><immunologic reactivity control><immunologic therapeutics><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunotherapeutics><immunotherapy agent><improved><in vitro activity><ipilimumab><mAbs><medical college><medical schools><metabolism measurement><metabolomics><metabonomics><mitochondrial><mitochondrial metabolism><monoclonal Abs><multi-modal therapy><multi-modal treatment><neoplastic cell><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pathway><patient response><patient specific response><pre-clinical><preclinical><preparations><recruit><research and development><resistant><response><response to therapy><response to treatment><responsive patient><school of medicine><skills><social role><tandem mass spectrometry><therapeutic response><therapy response><thymus derived lymphocyte><tool><transplant><treatment response><treatment responsiveness><treatment strategy><trial regimen><trial treatment><tumor><tumor growth><tumor microenvironment>